Renerve Limited (ASX:RNV) has popped by nearly +50% (on fairly illiquid trades) as the company reports 13 patients using ReNerve’s ‘Nerve Cuff’ product led to a reduction of pain following surgery for nerve damage.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The ‘Nerve Align Nerve Cuff’ is technically a medical device – think of it like a small filmy bandage – which is wrapped around nerves at the final stages of nerve-based surgery to promote recovery and prevent scarring, with the film absorbed into the body over six months.
For anyone who’s ever had to wear dissolving stitches (or had their child get them,) it’s pretty much the same idea.
Except ReNerve’s Nerve Cuff product – the film that dissolves – comes from the membrane that surrounds pig hearts, the porcine pericardium. Presumably, this could cause some marketability issues with some people of certain faiths.
(But that’s slightly beside the point, I’d admit.)
Key to the price jump on Friday is patients are reporting greatly reduced pain on a score from ‘7’ down close to ‘0.’ While self-reporting-based surveys are always hard to truly actualise, it’s promising responses.
From at least thirteen Renerve patients in the reporting, anyway.
More market news
Never-ending: And just like that, Trump’s tariffs are back causing more market chaos
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
“Patients treated with the Nerve Cuff also reported higher satisfaction with their surgery compared to those that did not receive the Nerve Cuff,” ReNerve wrote on Friday. “93% of patients with the Nerve Cuff said they would elect to have surgery again vs. 70% of patients without the Nerve Cuff.”
That the patients have reported satisfaction with the Nerve Cuff product as an accessory product to surgery has been presented to a conference in Arizona.
RNV last traded at 16cps.
Join the discussion: See what HotCopper users are saying about Renerve Limited and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.